Thomson Horstmann & Bryant Inc. decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 6.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 132,095 shares of the company’s stock after selling 8,863 shares during the period. Thomson Horstmann & Bryant Inc. owned 0.36% of Omnicell worth $5,693,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. SFE Investment Counsel bought a new stake in Omnicell during the first quarter worth approximately $332,000. Legato Capital Management LLC boosted its stake in Omnicell by 3,965.0% in the first quarter. Legato Capital Management LLC now owns 42,154 shares of the company’s stock worth $1,037,000 after buying an additional 41,117 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Omnicell by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock worth $614,000 after buying an additional 400 shares during the last quarter. Juncture Wealth Strategies LLC boosted its stake in Omnicell by 7.2% in the first quarter. Juncture Wealth Strategies LLC now owns 29,692 shares of the company’s stock worth $1,207,000 after buying an additional 1,998 shares during the last quarter. Finally, First National Bank of Omaha bought a new stake in Omnicell during the first quarter worth approximately $865,000. 96.35% of the stock is owned by institutional investors and hedge funds.
Omnicell, Inc. (OMCL) traded up 2.24% on Friday, reaching $50.10. 227,601 shares of the company traded hands. Omnicell, Inc. has a one year low of $30.35 and a one year high of $51.98. The company’s market capitalization is $1.88 billion. The stock’s 50 day moving average price is $45.37 and its 200 day moving average price is $41.17.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.08 million. During the same period in the prior year, the firm posted $0.38 EPS. Omnicell’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, equities research analysts predict that Omnicell, Inc. will post $1.31 EPS for the current fiscal year.
OMCL has been the subject of a number of research reports. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price target on shares of Omnicell in a report on Tuesday, July 25th. Craig Hallum raised their price target on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Dougherty & Co raised their price target on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Piper Jaffray Companies restated a “hold” rating and issued a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Finally, BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $49.00.
In related news, Director Gary S. Petersmeyer sold 2,200 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $41.41, for a total transaction of $91,102.00. Following the sale, the director now directly owns 21,075 shares of the company’s stock, valued at approximately $872,715.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dan S. Johnston sold 16,400 shares of the stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $40.67, for a total transaction of $666,988.00. Following the sale, the executive vice president now directly owns 61,696 shares in the company, valued at $2,509,176.32. The disclosure for this sale can be found here. Insiders have sold a total of 199,823 shares of company stock worth $9,301,391 over the last three months. 3.77% of the stock is currently owned by insiders.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.